Medtronic, Bos Sci ordered to pay J&J about $1.2B for stent patents

The U.S. District Court in Delaware has awarded Johnson & Johnson (J&J) damages totaling $406.7 million and pre-judgment interest totaling $296 million from Boston Scientific and $521 million from Medtronic, in a case involving a stent patent owned by J&J.

Boston Scientific said it will appeal the judgment.

On Sept. 15, the U.S. Delaware District Court Judge Sue Robinson Monday granted J&J’s subsidiary, Cordis, a motion for final judgment against Boston Scientific and Medtronic, in their cases involving Cordis’ Palmaz balloon expandable stent patent.

The case relates to GFX and Microstent II from the Minneapolis-based Medtronic and the NIR stent from the Natick, Mass.-based Boston Scientific.

The original suit was filed in 1997, and Boston Scientific said it has not sold the NIR stent since 2004.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.